Stock Market

Apple (NASDAQ:AAPL) will deliver some of its upcoming artificial intelligence features this year through data centers powered by its own in-house chips, Bloomberg News reported on Thursday, as the iPhone maker looks to integrate generative AI in its products.

Emerson Electric Co. (NYSE: NYSE:EMR) reported a stronger-than-expected performance for its second quarter, with adjusted earnings per share (EPS) and revenue surpassing analyst projections. EMR shares were up 0.9% in premarket trading.

 U.S. stocks edged higher Tuesday, maintaining recent bullish optimism ahead of more corporate earnings and upcoming Fed speakers this week.

The best performers of the session on the Nifty 50 were Tata Consumer Products Ltd (NS:TACN), which rose 4.06% or 44.10 points to trade at 1,131.00 at the close. Meanwhile, Mahindra & Mahindra Ltd. (NS:MAHM) added 2.95% or 56.50 points to end at 1,972.45 and Bharat Petroleum Corp. Ltd. (NS:BPCL) was up 2.56% or 15.40 points to 616.10 in late trade.

Aspira Women’s Health Incorporated (AWH), in its Fourth Quarter and Full-Year 2023 Earnings Conference Call, detailed its financial and operational progress, highlighting a year-over-year revenue growth of 15% and advancements in women’s health diagnostics.

India stocks were higher after the close on Friday, as gains in the Power, Capital Goods and Public Sector Undertakings sectors led shares higher. At the close in NSE, the Nifty 50 rose 0.92%, while the BSE Sensex 30 index climbed 0.90%.

 U.S. stocks struggled for direction Thursday, as investors digested data that continue to suggest the economy is headed for a soft landing, though trading volumes were light ahead of key inflation headed into the long weekend.    

In a recent earnings call, evoke (formerly known as the company before rebranding) reported a 38% increase in revenue and a 41% growth in adjusted EBITDA for 2023, largely attributed to the acquisition of William Hill. Despite these gains, the company experienced an 8% pro forma revenue decline due to regulatory and compliance challenges.

The company explained that new data from two open-label Phase 1/2a studies and two open-label extension (OLE) studies of children and adolescents ages two to 18 with Dravet syndrome who were treated with STK-001 showed “clinically meaningful effects.”

U.S. stocks traded in a muted fashion Friday, still on course for strong weekly gains after expectations of interest rate cuts by the Federal Reserve.